Cosmetic Surgery Industry Lobbies Against The 'Botax' In Senate Health Bill 07 Dec 2009 "Leading makers of antiwrinkle drugs, breast implants and other appearance-related products are trying to derail a proposed tax on elective cosmetic surgery in the Senate's health-overhaul bill," The Wall Street Journal reports. "The proposed 5% levy -- dubbed the 'Botax' after the antiwrinkle treatment product Botox -- would raise an estimated $5.8 billion over 10 years." The tax proposal has raised the ire of the cosmetic surgery industry. "Two leading companies in aesthetic treatments, Allergan Inc. and Medicis Pharmaceutical Corp., are mounting lobbying and public-relations campaigns...